CATX
Perspective Therapeutics, Inc.Company with tickers: CATX
CIK
728387
CUSIP
46489V302
Shares Outstanding
114,046,197
Investor Relations
https://www.perspectivetherapeutics.com/
13F Activity (30d)
3 filings
2 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $28,357,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Research & Development | $21,372,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Operating Income | $-28,281,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Net Income | $-26,189,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $-0.25 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $-0.25 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |